Chromatin/Epigenetics

Epigenetics is the heritable modifications in gene expression that is not associated with changes in DNA sequence. Epigenetic modifications occur mostly on DNA or on the histone octamer. There are several types of epigenetics modifications, DNA methylation by DNA-methyl transferase (DNMT) and covalent modification of histones (e.g. acetylation, methylation, phosphorylation and ubiquitination). Histone acetylation by histone acetyltransferases (HATs) is involved in transcriptional activation, whereas histone deacetylation by histone deacetylases (HDACs) is connected with transcriptional repression. Histone demethylation is associated with lysine-specific demethylase (LSD) and JmjC domain containing histone demethylase (JHDM).
The nucleosome is consisted of four histone proteins (H2A, H2B, H3, and H4), they are primary building block of chromatin. The addition and removal of specific chemical groups refers to as epigenetic marks, it regulates chromatin structure and affects gene expression. Moreover, RNA is intimately involved in the formation of a repressive chromatin state.
Epigenetic mechanism responds to environmental changes at the cellular level and thus influences cellular plasticity. Chromatin and epigenetic regulation play a significant role in the programming of the genome during development and stress response, defects in epigenetics can lead to cancer, inflammation and metabolic disorders etc.
-   C3503 MS023 (hydrochloride)Summary: type I PRMTs inhibitor C3503 MS023 (hydrochloride)Summary: type I PRMTs inhibitor
-   B1141 Varenicline HydrochlorideSummary: α4β2 nicotinic receptor agonist B1141 Varenicline HydrochlorideSummary: α4β2 nicotinic receptor agonist
-   A9906 HDAC Set ISummary: For inhibiting HDAC A9906 HDAC Set ISummary: For inhibiting HDAC
-   B7819 CPI-1205Summary: EZH2 inhibitor B7819 CPI-1205Summary: EZH2 inhibitor
-   A8806 TMP269Summary: HDAC 4/5/7/9 inhibitor A8806 TMP269Summary: HDAC 4/5/7/9 inhibitor
-   B7806 HLCL-61Summary: PRMT5 inhibitor B7806 HLCL-61Summary: PRMT5 inhibitor
-   A8803 RGFP9664 CitationTarget: Histone Deacetylases (HDACs)Summary: Specific HDAC3 inhibitor A8803 RGFP9664 CitationTarget: Histone Deacetylases (HDACs)Summary: Specific HDAC3 inhibitor
-   B8023 Cerdulatinib (PRT062070)Target: JAK|Syk|TYK2Summary: Syk/JAK inhibitor B8023 Cerdulatinib (PRT062070)Target: JAK|Syk|TYK2Summary: Syk/JAK inhibitor
-   B7757 UNC 0642Target: G9a|GLPSummary: G9a and GLP histone lysine methyltransferase inhibitor B7757 UNC 0642Target: G9a|GLPSummary: G9a and GLP histone lysine methyltransferase inhibitor
-   A8547 Tubastatin A HCl1 CitationTarget: Histone Deacetylases (HDACs)Summary: HDAC6 inhibitor,potent and selective A8547 Tubastatin A HCl1 CitationTarget: Histone Deacetylases (HDACs)Summary: HDAC6 inhibitor,potent and selective
